Onkológia 2/2017
Metastatic colorectal cancer – results of treatment of the primary tumor localization
The treatment of metastatic colorectal cancer (mCRC) is based on systemic chemotherapy in combination with biologic therapy. The median of overall survival (OS) of patients with metastatic colorectal cancer has improved to approximately 30 months due to more effective therapeutic combinations and more informations about tumors biology. Colorectal cancer was considered as a homogeneous entity for a long time. However, regarding morphology we recognize several subtypes of carcinomas which differ at molecular genetic level.
Keywords: metastatic colorectal cancer, right-sided primary tumor, left-sided primary tumor, epidermal growth factor receptor (antiEGFR), inhibitor, vascular endothelial growth factor (VEGF) inhibitor, RAS, BRAF mutations
